[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
9-Jan-2014

[ | E-mail ] Share Share

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Researchers discover a tumor suppressor gene in a very aggressive lung cancer

IMAGE: This is a photo of the IDIBELL genes and cancer group.

Click here for more information.

In addition to identifying the tumor suppressor role of MAX in lung cancer, the group led by Montse Sanchez-Cespedes has unveiled a functional relationship between MAX and another tumor suppressor, BRG1, in virtue of which BRG1 regulates the expression of MAX through direct recruitment to the MAX promoter. However, the functional connection is even more complex. On one hand, the presence of BRG1 is required to activate neuroendocrine transcriptional programs and to up-regulate MYC-targets, such as glycolytic-related genes. Moreover, the depletion of BRG1 strongly hinders cell growth, specifically in MAX-deficient cells, heralding a synthetic lethal interaction. The preferential toxicity of the inactivation of BRG1 in MAX-deficient lung cancer cells opens novel therapeutic possibilities for the treatment of SCLC patients with MAX-deficient tumors.

The Genes and Cancer group has identified several genes altered in lung cancer. Among these is BRG1 (also called SMARCA4) and the latest generation-sequencing technologies have extended these findings to other tumor types evidencing that BRG1 inactivation is widespread in cancer. BRG1 encodes one ATPase of the SWI/SNF chromatin remodeling complex and Dr. Sanchez-Cespedes group had previously shown that loss of BRG1 is closely related to the activation of MYC in lung cancer. Both conditions are mutually exclusive and act preventing cell differentiation and promoting cell growth. The current discovery that MAX acts as a tumor suppressor in lung cancer provides evidence that an aberrant SWI/SNF-MYC/MAX network is essential for lung cancer development.

###

Reference:

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discovery. 2013 Dec 20. [Epub ahead of print].

Related references:

Romero OA, Sanchez-Cespedes M.The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene. 2013 Jun 10. [Epub ahead of print]

Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M.The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med. 2012 Jul;4(7):603-16.

Referencia del artículo:

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discovery. 2013 Dec 20. [Epub ahead of print].

Articulos relacionados:

Romero OA, Sanchez-Cespedes M.The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene. 2013 Jun 10. [Epub ahead of print]

Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, Pisano D, Condom E, Villanueva A, Hager GL, Sanchez-Cespedes M.The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med. 2012 Jul;4(7):603-16.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.